{"protocolSection":{"identificationModule":{"nctId":"NCT03881852","orgStudyIdInfo":{"id":"AXS-12-201"},"organization":{"fullName":"Axsome Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)","officialTitle":"A Multi-center, Randomized, Double-blind, Placebo-controlled, 3-Week Crossover Study to Assess the Efficacy and Safety of AXS-12 in Subjects With Cataplexy and Excessive Daytime Sleepiness in Narcolepsy","acronym":"CONCERT"},"statusModule":{"statusVerifiedDate":"2026-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-04-05","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-11-27","type":"ACTUAL"},"completionDateStruct":{"date":"2019-11-27","type":"ACTUAL"},"studyFirstSubmitDate":"2019-03-15","studyFirstSubmitQcDate":"2019-03-18","studyFirstPostDateStruct":{"date":"2019-03-20","type":"ACTUAL"},"resultsFirstSubmitDate":"2022-12-07","resultsFirstSubmitQcDate":"2023-08-22","resultsFirstPostDateStruct":{"date":"2023-08-24","type":"ACTUAL"},"dispFirstSubmitDate":"2020-12-07","dispFirstPostDateStruct":{"date":"2023-08-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-05-26","lastUpdatePostDateStruct":{"date":"2026-06-15","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Axsome Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"CONCERT (Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment) is a Phase 2, double-blind, randomized, placebo-controlled, crossover, multicenter trial of AXS-12 in patients with narcolepsy. Subjects meeting the entry criteria will be randomized in a 1:1 ratio either to placebo for three weeks followed by AXS-12 (up to 10 mg daily) for three weeks, or to AXS-12 (up to 10 mg daily) for three weeks followed by placebo for three weeks. Efficacy assessments will include the frequency of cataplexy attacks, and measures of other symptoms of narcolepsy."},"conditionsModule":{"conditions":["Narcolepsy","Cataplexy Narcolepsy","Excessive Sleepiness"],"keywords":["CONCERT","AXS-12","EDS","Cataplexy","Narcolepsy","Axsome","Reboxetine"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"CROSSOVER","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":21,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"AXS-12 (reboxetine)","type":"EXPERIMENTAL","interventionNames":["Drug: AXS-12 (Reboxetine)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"AXS-12 (Reboxetine)","description":"Dosed orally, twice daily for up to 3 weeks","armGroupLabels":["AXS-12 (reboxetine)"]},{"type":"DRUG","name":"Placebo","description":"Dosed orally, twice daily for up to 3 weeks","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline in the Weekly Average Total Number of Cataplexy Attacks","description":"Presented as LSmeans. A positive change is indicative of improvement.","timeFrame":"2 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Male or female subjects between 18 and 70 years of age, inclusive\n* Primary diagnosis of narcolepsy with cataplexy\n* Willing and able to comply with the study requirements\n\nExclusion Criteria:\n\n* Other clinically significant conditions potentially causing EDS\n* Clinically significant psychiatric disorders","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"CONCERT Study Site","city":"Birmingham","state":"Alabama","zip":"35213","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"CONCERT Study Site","city":"Alameda","state":"California","zip":"94501","country":"United States","geoPoint":{"lat":37.77099,"lon":-122.26087}},{"facility":"CONCERT Study Site","city":"Santa Ana","state":"California","zip":"92705","country":"United States","geoPoint":{"lat":33.74557,"lon":-117.86783}},{"facility":"CONCERT Study Site","city":"Boulder","state":"Colorado","zip":"80301","country":"United States","geoPoint":{"lat":40.01499,"lon":-105.27055}},{"facility":"CONCERT Study Site","city":"Miami","state":"Florida","zip":"33126","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"CONCERT Study Site","city":"Gainesville","state":"Georgia","zip":"30501","country":"United States","geoPoint":{"lat":34.29788,"lon":-83.82407}},{"facility":"CONCERT Study Site","city":"Stockbridge","state":"Georgia","zip":"30281","country":"United States","geoPoint":{"lat":33.54428,"lon":-84.23381}},{"facility":"CONCERT Study Site","city":"Fort Wayne","state":"Indiana","zip":"46804","country":"United States","geoPoint":{"lat":41.1306,"lon":-85.12886}},{"facility":"CONCERT Study Site","city":"Chevy Chase","state":"Maryland","zip":"20815","country":"United States","geoPoint":{"lat":39.00287,"lon":-77.07115}},{"facility":"CONCERT Study Site","city":"The Bronx","state":"New York","zip":"10467","country":"United States","geoPoint":{"lat":40.84985,"lon":-73.86641}},{"facility":"CONCERT Study Site","city":"Cincinnati","state":"Ohio","zip":"45219","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"CONCERT Study Site","city":"Columbia","state":"South Carolina","zip":"29201","country":"United States","geoPoint":{"lat":34.00071,"lon":-81.03481}},{"facility":"CONCERT Study Site","city":"Austin","state":"Texas","zip":"78731","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"CONCERT Study Site","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Axsome Therapeutics Website","url":"http://www.axsome.com"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"Crossover Design: Subjects meeting the entry criteria will be randomized in a 1:1 ratio either to Sequence 1 \\[AXS-12 (up to 10 mg daily) for three weeks followed by placebo for three weeks\\] or Sequence 2 \\[placebo for three weeks followed by AXS-12 (up to 10 mg daily) for three weeks\\].","groups":[{"id":"FG000","title":"Sequence 1","description":"Sequence 1 - AXS-12 (reboxetine) for three weeks followed by placebo for three weeks"},{"id":"FG001","title":"Sequence 2","description":"Sequence 2 - Placebo for three weeks followed by AXS-12 (reboxetine) for three weeks"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"10"}]},{"type":"Dosed With AXS-12","achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"10"}]},{"type":"Dosed With Placebo","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"10"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"10"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety Population","groups":[{"id":"BG000","title":"Sequence 1","description":"Sequence 1 - AXS-12 (reboxetine) for three weeks followed by placebo for three weeks"},{"id":"BG001","title":"Sequence 2","description":"Sequence 2 - Placebo for three weeks followed by AXS-12 (reboxetine) for three weeks"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"21"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"32.3","spread":"12.44"},{"groupId":"BG001","value":"32.9","spread":"6.74"},{"groupId":"BG002","value":"32.6","spread":"9.90"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"17"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"14"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in the Weekly Average Total Number of Cataplexy Attacks","description":"Presented as LSmeans. A positive change is indicative of improvement.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"weekly cataplexy attacks","timeFrame":"2 weeks","groups":[{"id":"OG000","title":"AXS-12 (Reboxetine)","description":"AXS-12 (Reboxetine): Dosed orally, twice daily for up to 3 weeks"},{"id":"OG001","title":"Placebo","description":"Placebo: Dosed orally, twice daily for up to 3 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":"3.5"},{"groupId":"OG001","value":"-0.28","spread":"3.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","pValueComment":"P-value calculated from LSMean","statisticalMethod":"Mixed Models Analysis"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse events were collected from the randomization visit through 7 days after the last dosing date for non-serious AEs and 30 days after the last dosing for serious AEs.","description":"Safety Population includes all subjects who received study drug.","eventGroups":[{"id":"EG000","title":"AXS-12 (Reboxetine)","description":"Adverse events collected while subjects were in the AXS-12 (reboxetine) period of either Sequence 1 or Sequence 2.","deathsNumAffected":0,"deathsNumAtRisk":21,"seriousNumAffected":0,"seriousNumAtRisk":21,"otherNumAffected":9,"otherNumAtRisk":21},{"id":"EG001","title":"Placebo","description":"Adverse events collected while subjects were in the Placebo period of either Sequence 1 or Sequence 2.","deathsNumAffected":0,"deathsNumAtRisk":20,"seriousNumAffected":0,"seriousNumAtRisk":20,"otherNumAffected":8,"otherNumAtRisk":20}],"otherEvents":[{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Dictionary","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Dictionary","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Dictionary","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Dictionary","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Dictionary","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Dictionary","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Allergy to animal","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA Dictionary","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Blood pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Dictionary","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":20}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Dictionary","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Eructation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Dictionary","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Dictionary","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Dictionary","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Dictionary","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":20}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Dictionary","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Dictionary","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":20}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"pointOfContact":{"title":"Caroline Streicher, Senior Vice President, Clinical Operations","organization":"Axsome Therapeutics, Inc.","email":"cstreicher@axsome.com","phone":"212-332-5061"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan: Study Protocol and SAP","date":"2019-04-25","uploadDate":"2022-12-07T23:55","filename":"Prot_SAP_000.pdf","size":1184906},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan: SAP only","date":"2019-11-12","uploadDate":"2023-08-22T22:44","filename":"SAP_001.pdf","size":1031630}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2022-12-30","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D009290","term":"Narcolepsy"},{"id":"D006970","term":"Disorders of Excessive Somnolence"},{"id":"D002385","term":"Cataplexy"}],"ancestors":[{"id":"D020919","term":"Sleep Disorders, Intrinsic"},{"id":"D020920","term":"Dyssomnias"},{"id":"D012893","term":"Sleep Wake Disorders"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D001523","term":"Mental Disorders"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077593","term":"Reboxetine"}],"ancestors":[{"id":"D009025","term":"Morpholines"},{"id":"D010078","term":"Oxazines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}